<DOC>
	<DOCNO>NCT01056874</DOCNO>
	<brief_summary>This open label study estimate effect maraviroc pharmacokinetics digoxin , probe p-glycoprotein .</brief_summary>
	<brief_title>Effect Of Maraviroc On The Pharmacokinetics Of Digoxin</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Digoxin</mesh_term>
	<mesh_term>Maraviroc</mesh_term>
	<criteria>Healthy male and/or female subject age 21 55 year , inclusive . Body Mass Index ( BMI ) 17.5 25.5 kg/m2 . Total body weight &gt; 50 kg ( 110 lb ) . Treatment investigational drug within 30 day 5 halflives ( whichever longer ) precede first dose study medication . Subjects estimate creatinine clearance ( CLcr ) &lt; 80 ml/min . Pregnant nursing female . Females childbearing potential unwilling unable use acceptable method contraception outline protocol least 14 day prior first dose study medication completion study .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>Maraviroc</keyword>
	<keyword>Digoxin</keyword>
	<keyword>P-glycoprotein</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Drug Interaction</keyword>
	<keyword>HIV</keyword>
</DOC>